Buch, Englisch, 584 Seiten, Format (B × H): 165 mm x 240 mm, Gewicht: 1040 g
Buch, Englisch, 584 Seiten, Format (B × H): 165 mm x 240 mm, Gewicht: 1040 g
ISBN: 978-0-12-374344-2
Verlag: William Andrew Publishing
Zielgruppe
For medicinal, pharmaceutical, and organic chemists
Fachgebiete
- Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Pharmazeutische Technologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
- Naturwissenschaften Chemie Organische Chemie Biochemie
- Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
- Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
Weitere Infos & Material
Part I. Central Nervous System Diseases ¨C ROBICHAUD
Chapter 1 Recent Advances in Corticotropin Releasing Factor Receptor Antagonists
Carolyn D. Dzierba; Richard A. Hartz; Joanne J. Bronson
Chapter 2 Recent Advances on the 5-HT5A, 5-HT6 and 5-HT7 Receptors
Brock T. Shireman, Pascal Bonaventure and Nicholas I. Carruthers
Chapter 3 Recent Advances in Voltage Gated Sodium Channel Blockers: Therapeutic Potential as Drug Targets in the CNS
Andreas Termin, Esther Martinborough and Dean Wilson
Chapter 4 Medication Development for the Treatment of Substance Abuse
Brian Fulton
Part II. Cardiovascular and Metabolic Diseases - STAMFORD
Chapter 5 GPR40 (FFAR1) Modulators
Julio C. Medina and Jonathan B. Houze
Chapter 6 Rho-Kinase Inhibitors for Cardiovascular Disease
Robert A. Stavenger
Chapter 7 LXR Agonists for the Treatment of Atherosclerosis - Recent Highlights
Jonathan Bennett, Andrew Cooke, Heather J. McKinnon and Olaf Nimz
Chapter 8 Glucagon Receptor Antagonists for Type II Diabetes
DuaneE. DeMong, Michael W. Miller and Jean Lachowicz
Part III. Inflammation / Pulmonary / GI ¨C BARRISH
Chapter 9 Advances Towards Dissociated Non-Steroidal Glucocorticoid Receptor Agonists
John Regan, Hossein Razavi, David Thomson
Chapter 10 Advances in the Discovery of IkB Kinase Inhibitors
William J. Pitts and James Kempson
Chapter 11 Protease Inhibitors for the Potential Treatment of Chronic Obstructive Pulmonary Disease and Asthma
Weimin Liu and Eugene Hickey
Part IV. Oncology - MYLES
Chapter 12 mTor Inhibitors in Oncology
Jeroen Verheijen, Ker Yu and Arie Zask
Chapter 13 Oncology Drug Targets in the Sphingomyelin Signaling Path
Bill Garland, Amy Cavalli and Genevi¨¨ve Hansen
Part V. Infectious Diseases - Primeau
Chapter 14 Inhibitors of Respiratory Syncytial Virus
Malcolm Carter and G. Stuart Cockerill
Chapter 15 Recent Developments in ¦Â-Lactamases and Inhibitors
Tarek S. Mansour, Patricia A. Bradford and Aranapakam M. Venkatesan
Chapter 16 Recent Development in the Treatment of Clostridium Difficile Associated Disease (CDAD)
Xicheng Sun, Joseph Guiles and Nebojsa Janjic
Chapter 17 Recent Advances in the Discovery of Hybrid Antibacterial Agents
Mike Barbachyn
Part VI. Topics in Biology - LOWE
Chapter 18 Recent Renaissance of Prostaglandin Research
Robert Burk
Chapter 19 Human Exposure and Dose Projections
Punit H. Marathe, Christine Huang and A. David Rodrigues
Chapter 20 Modeling Networks of Glycolysis, Overall Energy Metabolism and Drug Metabolism under a Systems Biology Approach
Zoltan Sarnyai and Laszlo G. Boros
Part VII. Topics in Drug Design and Discovery ¨C DESAI
Chapter 21 Contrasting the Gastrointestinal Tracts of Mammals: Factors that Influence Absorption
John DeSesso and Amy Lavin Williams
Chapter 22 The Emerging Utility of Co-Crystals in Drug Discovery and Development
Nicholas Meanwell
Chapter 23 Pregnane X Receptor: Prediction and Attenuation of Human CYP3A4 Enzyme Induction and Drug-Drug Interactions
Michael W. Sinz
Chapter 24 Formulation in Drug Discovery
Robert Strictly
Part VIII. To Market, To Market
Chapter 25 To Market, To Market - 2007
Shridhar Hegde and Michelle Schmidt
